Brahmer JR et al. Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non–small cell lung cancer (NSCLC): Results from CheckMate 227. ASCO 2022;Abstract LBA9025.

de Castro G Jr et al. Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score ≥ 1% in the KEYNOTE-042 study. J Clin Oncol 2022;[Online ahead of print]. Abstract

Garassino M et al. KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC. ESMO 2022;Abstract 973MO.

Garon EB et al. Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study. ESMO 2021;Abstract LBA49.

Garon EB et al. TROPION-PanTumor01: Updated results from the NSCLC cohort of the phase 1 study of datopotamab deruxtecan in solid tumors. WCLC 2021;Abstract MA03.02.

Gogishvili M et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: A randomized, controlled, double-blind phase 3 trial. Nat Med 2022;28(11):2374-80. Abstract

Johnson ML et al. A phase 2 study of datopotamab deruxtecan (Dato-DXd) in advanced NSCLC with actionable genomic alterations (TROPION-Lung05). WCLC 2021;Abstract P47.05.

Johnson ML et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non–small-cell lung cancer: The phase III POSEIDON study. J Clin Oncol 2022;JCO.22.00975. Abstract

Johnson ML et al. Phase 1 and phase 2a, first-in-human (FIH) study, of DRP-104, a broad glutamine antagonist, in adult patients with advanced solid tumors. ASCO 2021;Abstract TPS3149.

Levy B et al. TROPION-Lung02: Initial results for datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy in advanced NSCLC. IASLC 2022;Abstract MA13.07.

Novello S et al. 5-year update from KEYNOTE-407: Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC). ESMO2022;Abstract 974MO.

Paz-Ares LG et al. First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA. ASCO 2022;Abstract 9026.

Reckamp KL et al. Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A. ASCO 2022;Abstract 9004.

Reckamp KL et al. Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with Immunotherapy-Lung-MAP S1800A. J Clin Oncol 2022;40(21):2295-306. Abstract